Subcutaneous semaglutide vs. placebo as adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity


What The Study Did:
This randomized clinical trial compares the effects of once-weekly subcutaneous semaglutide versussplacebo for weight management as an adjunct to intensive behavioral therapy with initial low-calorie diet in adults with overweight or obesity.

Thomas A. Wadden, Ph.D., of the University of Pennsylvania in Philadelphia, is the corresponding author.

To access the embargoed study:
Visit our For The Media website at this link


Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.


Media advisory:
The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article 
This link will be live at the embargo time

Media Contact
JAMA Network Media Relations
[email protected]

Leave A Reply

Your email address will not be published.